Rafael(RFL) - 2025 Q3 - Quarterly Results

"We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48- week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, "We have enhanced our financial position with the closing of a $25 million rights of ...